TARKA® (trandolapril/verapamil hydrochloride ER)
TARKA® (trandolapril/verapamil hydrochloride ER)
Chemical composition:
TARKA® consists of a combination of slow release formula of Verapamil (Calcium channel blocker) and immidiate release formula of Trandolapril (ACE inhibitor)
Verapamil formulated as verapamil hydrochloride which is white crystalline powder soluble in water and alcohol, odourless and has bitter taste. Trandolapril is the ethyl ester of the active forumla tradolaprilate. Trandolapril is colourless crystalline powder soluble in methanol and chloroform
TARKA also contains the following ingredients: lactose, microcrystalline cellulose, ethanol, corn starch, dioctyl sodium sulfosuccinate, hydroxypropyl cellulose, hypromellose, , magnesium stearate, polyethylene glycol, silicon dioxide, povidone, purified water ,sodium stearyl fumarate, sodium alginate, talc, synthetic iron oxides, and titanium dioxide.
TARKA® has 4 strengthes 2/180mg, 1/240mg, 2/240mg, 4/240mg as trandolapril/verapamil.
Mode of action:
Tarka exerts its action in two phases, Rapid immidiate action induced by the angiotensin converting enzyme inhibitor trandolapril and delayed pronlonged action induced by the calcium channel blocker verapamil. Trandolapril acts by inhibiting the angiotensin converting enzyme resulting in inhibition of angiotensin activation from its inactive form angiotensinogen and this will stop its vasoconstriction effect. Verapamil causes blockade of the calcium channels resulting in inhibiton of calcium influx inside the vascular smooth muscles leading to its relaxation and vasodilation.
Contraindications:
Tarka is contraindicated in patients having hypersenstivity to verapamil or trandolapril also it’s contraindicated in hypotension, ventricular dysfunction, AV block, atrial fibrillation
Tarka should be completley avoided during pregnancy as its fatal to neonates.
